Foundry Healthcare OPLev Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1UNH | UNITEDHEALTH GROUP INC | Healthcare | $386.95B | 30.52% |
2CVS | CVS HEALTH CORP | Healthcare | $137.12B | 10.81% |
3MCK | MCKESSON CORP | Healthcare | $101.14B | 7.98% |
4ELV | ELEVANCE HEALTH INC | Healthcare | $80.92B | 6.38% |
5CI | CIGNA GROUP | Healthcare | $74.45B | 5.87% |
6COR | CENCORA INC | Healthcare | $59.91B | 4.72% |
7CAH | CARDINAL HEALTH INC | Healthcare | $53.52B | 4.22% |
8HUM | HUMANA INC | Healthcare | $48.02B | 3.79% |
9IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 3.53% |
10NTRA | NATERA INC | Healthcare | $38.87B | 3.07% |
11CNC | CENTENE CORP | Healthcare | $32.81B | 2.59% |
12MEDP | MEDPACE HOLDINGS INC | Healthcare | $15.36B | 1.21% |
13BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $13.71B | 1.08% |
14MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $12.76B | 1.01% |
15AXSM | AXSOME THERAPEUTICS INC | Healthcare | $11.84B | 0.93% |
16MOH | MOLINA HEALTHCARE INC | Healthcare | $11.74B | 0.93% |
17SMMT | SUMMIT THERAPEUTICS INC | Healthcare | $10.72B | 0.85% |
18ENSG | ENSIGN GROUP INC | Healthcare | $10.01B | 0.79% |
19HSIC | HENRY SCHEIN INC | Healthcare | $10.00B | 0.79% |
20UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $9.15B | 0.72% |
21OSCR | OSCAR HEALTH INC | Healthcare | $8.77B | 0.69% |
22PACS | PACS GROUP INC | Healthcare | $7.30B | 0.58% |
23CHE | CHEMED CORP | Healthcare | $6.77B | 0.53% |
24HNGE | HINGE HEALTH INC | Healthcare | $6.74B | 0.53% |
25ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $4.26B | 0.34% |
26OPCH | OPTION CARE HEALTH INC | Healthcare | $3.41B | 0.27% |
27PRVA | PRIVIA HEALTH GROUP INC | Healthcare | $3.39B | 0.27% |
28WRBY | WARBY PARKER INC | Healthcare | $3.24B | 0.26% |
29TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $2.58B | 0.20% |
30GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $2.57B | 0.20% |
31ASTH | ASTRANA HEALTH INC | Healthcare | $2.50B | 0.20% |
32PGNY | PROGYNY INC | Healthcare | $2.50B | 0.20% |
33BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.19% |
34AGL | AGILON HEALTH INC | Healthcare | $2.17B | 0.17% |
35MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.15B | 0.17% |
36ADUS | ADDUS HOMECARE CORP | Healthcare | $2.14B | 0.17% |
37AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.11B | 0.17% |
38CDNA | CAREDX INC | Healthcare | $2.05B | 0.16% |
39WGS | GENEDX HOLDINGS CORP | Healthcare | $1.88B | 0.15% |
40NVCR | NOVOCURE LTD | Healthcare | $1.84B | 0.15% |
41HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.74B | 0.14% |
42FTRE | FORTREA HOLDINGS INC | Healthcare | $1.68B | 0.13% |
43INNV | INNOVAGE HOLDING CORP | Healthcare | $1.56B | 0.12% |
44PNTG | PENNANT GROUP INC | Healthcare | $1.46B | 0.12% |
45INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.11% |
46ARDT | ARDENT HEALTH INC | Healthcare | $1.46B | 0.11% |
47OMDA | OMADA HEALTH INC | Healthcare | $1.41B | 0.11% |
48AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.36B | 0.11% |
49PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.35B | 0.11% |
50ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.31B | 0.10% |
51ARDX | ARDELYX INC | Healthcare | $1.28B | 0.10% |
52TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 0.09% |
53ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.16B | 0.09% |
54TALK | TALKSPACE INC | Healthcare | $873M | 0.07% |
55PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $873M | 0.07% |
56SIBN | SI-BONE INC | Healthcare | $771M | 0.06% |
57CBLL | CERIBELL INC | Healthcare | $710M | 0.06% |
58SPRY | ARS PHARMACEUTICALS INC | Healthcare | $695M | 0.05% |
59EVH | EVOLENT HEALTH INC | Healthcare | $654M | 0.05% |
60TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.05% |
61ACHV | ACHIEVE LIFE SCIENCES INC | Healthcare | $644M | 0.05% |
62MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.05% |
63WEAV | WEAVE COMMUNICATIONS INC | Healthcare | $575M | 0.05% |
64ANGO | ANGIODYNAMICS INC | Healthcare | $558M | 0.04% |
65NPCE | NEUROPACE INC | Healthcare | $548M | 0.04% |
66TOI | ONCOLOGY INSTITUTE INC | Healthcare | $535M | 0.04% |
67NRC | NRC HEALTH | Healthcare | $491M | 0.04% |
68OFIX | ORTHOFIX MEDICAL INC | Healthcare | $468M | 0.04% |
69VMD | VIEMED HEALTHCARE INC | Healthcare | $466M | 0.04% |
70CCRN | CROSS COUNTRY HEALTHCARE INC | Healthcare | $428M | 0.03% |
71EOLS | EVOLUS INC | Healthcare | $377M | 0.03% |
72FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $365M | 0.03% |
73ELMD | ELECTROMED INC | Healthcare | $349M | 0.03% |
74CV | CAPSOVISION INC | Healthcare | $335M | 0.03% |
75SGHT | SIGHT SCIENCES INC | Healthcare | $274M | 0.02% |
76SMTI | SANARA MEDTECH INC | Healthcare | $229M | 0.02% |
77KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.02% |
78SENS | SENSEONICS HOLDINGS INC | Healthcare | $214M | 0.02% |
79BDSX | BIODESIX INC | Healthcare | $204M | 0.02% |
80FOCL | FOCAL INC | Healthcare | $204M | 0.02% |
81PDEX | PRO DEX INC | Healthcare | $183M | 0.01% |
82INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.01% |
83INGN | INOGEN INC | Healthcare | $178M | 0.01% |
84OWLT | OWLET INC | Healthcare | $162M | 0.01% |
85RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.01% |
86JYNT | JOINT CORP | Healthcare | $127M | 0.01% |
87VRCA | VERRICA PHARMACEUTICALS INC | Healthcare | $96M | 0.01% |
88CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.01% |
89NRXS | NEURAXIS INC | Healthcare | $84M | 0.01% |
90FRMM | FORUM MARKETS INC | Healthcare | $83M | 0.01% |
91PIII | P3 HEALTH PARTNERS INC | Healthcare | $78M | 0.01% |
92ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.01% |
93SCLX | SCILEX HOLDING CO | Healthcare | $72M | 0.01% |
94LNSR | LENSAR INC | Healthcare | $70M | 0.01% |
95SNWV | SANUWAVE HEALTH INC | Healthcare | $55M | 0.00% |
96EXOZ | EXOZYMES INC | Healthcare | $51M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $1.27T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 97% toward Large, 53% toward Growth. +1% unclassified (16 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 96 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual63.4%Margin-11.6%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual30.5%Margin-5.5%
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 96 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 28%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 41.6% | -30.5% |
| 3 yearsp.a. | 2.6% | -21.4% |
| 5 yearsp.a. | 3.5% | -3.3% |
| 10 yearsp.a. | 10.6% | -1.5% |
| Since inceptionp.a. | 12.1% | -2.6% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 14.0% | -15.2% |
| 2025 | -0.5% | -34.8% |
| 2024 | -7.8% | -8.2% |
| 2023 | 1.7% | -7.4% |
| 2022 | 0.6% | 47.9% |
| 2021 | 31.6% | 14.4% |
| 2020 | 19.8% | -26.1% |
| 2019 | 22.0% | -12.7% |
| 2018 | 8.8% | 36.7% |
| 2017 | 24.5% | 12.4% |
| 2016 | 1.5% | 39.0% |
| 2015 | 9.1% | 9.4% |
| 2014 | 30.4% | 8.3% |
| 2013 | 46.3% | -7.1% |
| 2012 | 12.5% | -16.2% |
| 2011 | 15.1% | -5.8% |
| 2010 | 16.3% | 9.7% |
| 2009 | 30.5% | 10.4% |
| 2008 | -42.1% | -42.8% |
| 2007 | 14.2% | 27.7% |
| 2006 | -0.1% | 5.8% |
| 2005 | 29.5% | 11.8% |
| 2004 | 24.9% | 17.0% |
| 2003 | 35.1% | -20.1% |
| 2002 | 0.7% | 76.7% |
| 2001 | -9.1% | -1.8% |
| 2000 | 98.8% | -18.9% |
| 1999 | -23.8% | -62.9% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare OPLev Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a OPLev signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.